1. In Vivo

Israel’s Authority On Medical Robotics Lifts Curtain Behind Technion’s Success Stories

 
• By Marion Webb

Moshe Shoham talks about the innovative technologies behind surgical robotics companies Microbot Medical, XACT Robotics, Tamar Robotics and ForSight Robotics, which were all spun out of his laboratory in Israel.    

Robot hand and human finger

In the field of medical robotics, Moshe Shoham needs no introduction. An acclaimed authority of medical robotics, Shoham is one of the few Israelis to be elected to the US National Academy of Engineering and as founder and leader of the medical robotics laboratory at the Technion-Israel Institute of Technology has a long history of spin-out companies, including spine surgery company Mazor Robotics Ltd., which was acquired by Medtronic in 2018 in a $1.6bn deal.

In an interview with In Vivo, Shoham noted that medical robotics has come a long way since he started his...

More from New Science

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.